Suscribirse

Statin Use in Hospitalized Patients with COVID-19: A Comprehensive Analysis of the New York City Public Hospital System - 16/06/22

Doi : 10.1016/j.amjmed.2022.02.018 
Weijia Li a, Saul Rios, MD a, , Sanjana Nagraj, MD a, Adrija Hajra, MD a, Tinatin Saralidze, MD a, Dimitrios Varrias, MD a, Sheetal Vasundara Mathai, MD a, Marko Novakovic, MD a, Kenneth H. Hupart, MD b, Jeremy A. Miles, MD a, Adarsh Katamreddy, MD a, Leonidas Palaiodimos, MD a, Robert T. Faillace, MD a
a Department of Medicine, New York City Health + Hospitals/Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY 
b Department of Medicine, New York City Health + Hospitals/Coney Island Brooklyn NY, Albert Einstein College of Medicine, Bronx, NY 

Requests for reprints should be addressed to Saul Rios, MD, Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, 1400 Pelham Parkway South, Bronx, NY, 10461.Department of MedicineJacobi Medical CenterAlbert Einstein College of Medicine1400 Pelham Parkway SouthBronxNY10461

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Introduction

Statins have been commonly used for primary and secondary cardiovascular prevention. We hypothesized that statins may improve in-hospital outcomes for hospitalized patients with Coronavirus disease 2019 (COVID-19) due to its known anti-inflammatory effects.

Methods

We conducted a retrospective study at the largest municipal health care system in the United States, including adult patients who were hospitalized for COVID-19 between March 1 and December 1, 2020. The primary endpoint was in-hospital death. Propensity score matching was conducted to balance possible confounding variables between patients receiving statins during hospitalization (statin group) and those not receiving statins (non-statin group). Multivariate logistic regression was used to evaluate the association of statin use and other variables with in-hospital outcomes.

Results

There were 8897 patients eligible for study enrollment, with 3359 patients in the statin group and 5538 patients in the non-statin group. After propensity score matching, both the statin and non-statin groups included 2817 patients. Multivariate logistic regression analysis showed that the statin group had a significantly lower risk of in-hospital mortality (odds ratio 0.71; 95% confidence interval, 0.63-0.80; P < .001) and mechanical ventilation (OR 0.80; 95% confidence interval, 0.71-0.90; P < .001) compared with the non-statin group.

Conclusion

Statin use was associated with lower likelihood of in-hospital mortality and invasive mechanical ventilation in hospitalized patients with COVID-19.

El texto completo de este artículo está disponible en PDF.

Keywords : COVID-19, In-hospital mortality, Mechanical ventilation, Statin


Esquema


 Funding: None.
 Conflicts of Interest: None.
 Authorship: All authors had access to the data and contributed to writing the manuscript.
 This work was approved by the Biomedical Research Alliance of New York (BRANY) Institutional Review Board (IRB number 20-12-228-373).


© 2022  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 135 - N° 7

P. 897-905 - juillet 2022 Regresar al número
Artículo precedente Artículo precedente
  • Blood Pressure Trajectories and Outcomes for Veterans Presenting at VA Medical Centers with a Stroke or Transient Ischemic Attack
  • Greg Arling, Anthony Perkins, Laura J. Myers, Jason J. Sico, Dawn M. Bravata
| Artículo siguiente Artículo siguiente
  • Non-Exercise Estimated Cardiorespiratory Fitness and Incident Hypertension
  • Palakben Hasmukhbhai Patel, Mitchell Gates, Peter Kokkinos, Carl J. Lavie, Jiajia Zhang, Xuemei Sui

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.